is an excellent target for candidiasis regulation.

K8. These findings show that MSF is a potential defensin inducer and anti-inflammatory agent.

. Sclareol is of high interest as a novel anti-fungal agent and anti-virulence factor.

is an excellent target for candidiasis regulation.

K8. These findings show that MSF is a potential defensin inducer and anti-inflammatory agent.

. Sclareol is of high interest as a novel anti-fungal agent and anti-virulence factor.

. Pectolinarin reduced the bacterial biofilm formation, activated the antibacterial susceptibility, and reduced the bacterial adherence. These results suggest that bacterial biofilm formation is a good target to develop the antibacterial agents against biofilm-related infections.

BMSE-HMP251, which showed species-consistent phenotypic and genomic characteristics and no safety concerns. Overall, fermentation markedly enhances the anti-inflammatory potential of plant-derived EVs, supporting fermentation as a safe and effective strategy to improve their functional value.

LB1022 synbiotic mitigates both epidermal and respiratory allergic inflammation through coordinated regulation of the microbiota-gut-skin-lung axis. The findings highlight a promising dietary approach for reducing the risk of progression along the atopic march and address an important gap in current allergy-related microbiome research.

BACKGROUND: Cholesterol is considered a major factor contributing to cardiovascular diseases. Statins, the most commonly prescribed cholesterol-lowering drugs, are known to have various limitations. Inhibition of Adenosine Triphosphate-Citrate Lyase (ACLY) has been proposed as an alternative therapeutic strategy for managing hypercholesterolemia by lowering cholesterol levels. This has led to the discovery of a cell-permeable small molecule ACLY inhibitor. METHODS: ACLY enzyme activity was assessed using an ACLY Assay Kit with the ADP-Glo Kinase Assay Kit. HepG2 cells were treated with test compounds to demonstrate cholesterol and fatty acid synthesis. Pharmacokinetic studies were performed on CD-1 mice following a single oral dose of the compounds. Hypercholesterolemia was induced in mice through a High-Fat and High Cholesterol Diet (HFHCD), and drugs were administered orally for six weeks. Serum and hepatic lipid profiles were subsequently analyzed. RESULTS: : 45 nM, 10-fold lower than BMS- 303141) and achieved near-complete suppression in cholesterol and fatty acid synthesis at the highest concentration. Pharmacokinetic studies revealed improved half-lives and systemic exposures for all analogues. In hypercholesterolemic mouse models, test compounds significantly reduced serum total cholesterol (32.0-57.3%) and low-density lipoprotein cholesterol (67.5-80.2%) levels compared to the vehicle group. Notably, ID0085 also increased high-density lipoprotein cholesterol levels. DISCUSSION: Among the synthesized analogues, ID0085 exhibited the most potent ACLY inhibition, superior pharmacokinetic properties, and significant improvements in both serum and hepatic cholesterol profiles compared to BMS-303141. CONCLUSION: Based on the results, ID0085 appears to be the most promising therapeutic candidate for the treatment of hypercholesterolemia.